Neurocrine Biosciences will soon launch its second wholly owned commercial product, Crenessity (crinecerfont) for classic congenital adrenal hyperplasia (CAH), adding what the company sees as another blockbuster opportunity for its portfolio. Analyst expectations for the drug’s sales are mixed, but Neurocrine has a first-to-market advantage in a disease with no new treatments in 70 years and its next competitor is likely a few years away from reaching patients.
Neurocrine’s Crenessity Is The First New Drug For CAH In 70 Years
Next Competitor Likely Years Behind
Neurocrine will launch Crenessity for adults and children with classic congenital adrenal hyperplasia in less than a week, with pricing available then, adding its second commercial product.
More from Drug Pricing
• By
Lilly’s Mounjaro arrives in India, with the 2.5mg vial priced at under $41 in a market that has over 100 million diabetics and increasing obesity rates. Will the product see sharp demand like in China, carving out a chunk of the pie ahead of the potential arrival of semaglutide generics and could there be concerns of ‘suitcase' exports?
• By
The development could highlight the power of competitive market forces over government price controls or suggest Medicare price negotiation is enhancing competitive market forces.
• By
Amvuttra will target a substantially larger patient population with a new indication, but it is third to market behind Pfizer’s Vyndaqel and Bridge Bio’s Attruby and will cost more.
• By
Policy advances, measures to back local production and crowdfunding action for gene therapies like Zolgensma bring hope for rare disease patients in India. Gaps in financing, high prices and an ongoing court case, however, stunt efforts to ensure timely access.
More from Scrip
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
• By
By allowing it to enter the brain more easily, trontinemab’s brain shuttle brings more patients to ‘amyloid zero’ levels faster, and with fewer brain swelling side effects.
• By
Compass' bispecific antibody tovecimig hits primary efficacy endpoint in Phase II/III top-line data in advanced biliary tract cancer, and may have class side-effect advantages. But additional survival data may be needed to support US approval.